Business Wire

ACURIS-RISK-INTELLIGENCE

11.12.2018 12:02:03 CET | Business Wire | Press release

Share
Acuris Risk Intelligence Celebrates 350 Direct Customers and Wins Compliance Awards

Acuris Risk Intelligence , a trusted and independent provider of data intelligence for Anti-Money Laundering, Third Party Risk and Cyber Security professionals, today announces that it now serves 350 direct customers worldwide, helping them to mitigate risk and effectively comply with regulations. This significant milestone nearly doubles its direct client base compared to this time last year and is only two months since the relaunch of the brand, formerly known as C6.

Whilst the business has been successful since its inception in 2004 in selling its data via major channel partners, this is a noteworthy milestone as it reflects the success of focusing on direct customer outreach. The business continues to work with some of the biggest compliance platforms in the world as an integrated provider.

Acuris Risk Intelligence has also won FinTech/RegTech Rising Star and Best Financial Crime Intelligence Data at The Compliance Register Platinum Awards 2018 as well as executing a successful expansion into the Asia Pacific region, serving 32 customers across 10 sectors including Investment banking, Private Equity Funds, Corporates, Casinos and Data Providers

“Following our rebrand in October, we’re delighted to have achieved these successes as we continue our growth path with Acuris,” states Joel Lange, Managing Director, Acuris Risk Intelligence. “Our offering is popular with companies who want the best protection and compliance monitoring integrated into their businesses operations. We look forward to further expanding this offering in the months and years to come.”

A substantial investment into a more API driven approach has proven commercially beneficial, boosting the systems used to reveal the risks associated with business relationships. This process also offers customers a seamless and cost-effective integration process into their many compliance workflows, which is fully customisable and tailored to the customer’s specific internal business requirements.

In addition, the company is working on a large development plan called Project Revolution, which aims to implement major enhancements to both the brand’s products and data. The goal of Project Revolution is to take our already solid product and revolutionise the 3 core pillars:

  • We aim to enrich the data model that underpins our system giving more breadth of information on all our profiles allowing our customers to better integrate content with other data sets.
  • We are redesigning our matching algorithm to provide an easy to understand match score and improved accuracy thus further reducing false positives.
  • By revamping our research methodology including the best of automation technologies that our research team use to capture our data, we will have more relevant data points, more complete profiles and even improved timeliness of content.

“It’s great to see the Acuris Risk Intelligence brand grow so quickly and this is only the beginning of the journey,” Hamilton Matthews, CEO at Acuris commented. “The next phase will continue to build on the solid foundation that we have developed over the years, ensuring that businesses continue to lessen their exposure to threats while complying with increasingly strict regulations”.

Acuris Risk Intelligence brings together world-class data, human expertise and the latest technology to help businesses manage risk and compliance in real time. So instead of a never-ending, escalating cost, risk management becomes part of business as usual. Acuris Risk Intelligence is here to make that vision a reality.

About Acuris Risk Intelligence

Acuris Risk Intelligence was established in 2004 as C6 and rose to become one of the top suppliers of proprietary data on PEPs, sanctions and adverse media data for due diligence and compliance. It was acquired by Acuris in 2015. Today, Acuris Risk Intelligence combines a world-class dataset – that now includes fraud and cyber security content – with expert human analysts and state-of-the-art technology to help organisations manage the risk in business relationships effectively. Clients access our intelligence via a SaaS platform, or via API and feed technology so risk protection is built into the way they operate. Our focus areas include Anti-Money Laundering, Third Party Risk and Cyber Security. For more information, please visit us at Acuris Risk Intelligence.com or call us on +44 (0) 203 742 1200.

Contact:

Acuris Risk Intelligence Brooke Petersen Head of Marketing & Customer Success T: +44 (0) 203 741 1198 E: Brooke.Petersen@Acuris.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release

A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye